Trends, Management and Outcomes of Acute Myocardial Infarction in Chronic Liver Disease by Matetic , Andrija et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ijcp.13841
 This article is protected by copyright. All rights reserved
DR ANDRIJA  MATETIC (Orcid ID : 0000-0001-9272-6906)
DR MOHAMED OSAMA MOHAMED (Orcid ID : 0000-0002-9678-5222)
Article type      : Original Paper
Trends, Management and Outcomes of Acute Myocardial Infarction in Chronic Liver Disease
Short title: AMI outcomes in liver disease patients
Andrija Matetic, MDa,b*, Tahmeed Contractor, MDc*, Mohamed O. Mohamed, MRCP(UK)d,e, Rahul 
Bhardwaj, MDc, Ashish Anejaf, Phyo K. Myint, MDg, Mina O. Rakoski, MD MSch, Shelley Zierothi, 
Timir K. Paul, MD, PhDj, Mamas A. Mamas, DPhild,e
*Joint first authors; contributed to manuscript equally
(a) Department of Cardiology, University Hospital of Split, Split, Croatia
(b) Department of Pathophysiology, University of Split School of Medicine, Split, Croatia
(c) Department of Cardiology, Loma Linda University, Loma Linda, CA, USA
(d) Keele Cardiovascular Research Group, Centre for Prognosis Research, Institutes of Applied 
Clinical Science and Primary Care and Health Sciences, Keele University, UK 
(e) Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, UK
(f) MetroHealth Heart and Vascular, Case Western Reserve University, Cleveland, OH, USA
(g) Institute of Applied Health Sciences, University of Aberdeen
(h) Department of Gastroenterology and Hepatology, Loma Linda University, Loma Linda, CA, 
USA
(i) Section of Cardiology, University of Manitoba, Winnipeg, Canada









This article is protected by copyright. All rights reserved




Keele Cardiovascular Research Group,
Centre for Prognosis Research, 
Institute for Primary Care and Health Sciences, Keele University, UK
mamasmamas1@yahoo.co.uk
Declarations of interest: None
Word count (manuscript text): 3,450
Abstract: 
Aims: There is limited data on the management and outcomes of chronic liver disease (CLD) patients 
presenting with acute myocardial infarction (AMI), particularly according to the subtype of CLD.
Methods: Using the Nationwide Inpatient Sample (2004-2015), we examined outcomes of AMI 
patients stratified by severity and sub-types of CLD. Multivariable logistic regression was performed 
to assess the adjusted odds ratios (aOR) of receipt of invasive management and adverse outcomes in 
CLD groups compared with no-CLD. 
Results: Out of 7,024,723 AMI admissions, 54,283 (0.8%) had a CLD diagnosis. CLD patients were 
less likely to undergo coronary angiography (CA) and percutaneous coronary intervention (PCI) (aOR 
0.62, 95%CI 0.60-0.63 and 0.59, 95%CI 0.58-0.60, respectively), and had increased odds of adverse 
outcomes including major adverse cardiovascular and cerebrovascular events (1.19, 95%CI 1.15-
1.23), mortality (1.30, 95%CI 1.25-1.34) and major bleeding (1.74, 95%CI 1.67-1.81). In comparison 
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CA and PCI (p<0.05). Amongst severe CLD patients, those with alcohol-related liver disease (ALD) 
had the lowest utilization of CA and PCI; patients with ALD and other CLD (OCLD) had more 
adverse outcomes than the viral hepatitis sub-group (p<0.05).
Conclusions: CLD patients presenting with AMI are less likely to receive invasive management and 
are associated with worse clinical outcomes. Further differences are observed depending on the type 
as well as severity of CLD, with the worst management and clinical outcomes observed in those with 
severe ALD and OCLD.
Key words: acute myocardial infarction; chronic liver disease; in-hospital outcomes.
What’s known? There is limited data on management strategies and clinical outcomes of CLD 
patients when presenting with AMI from a national perspective. There have been only small studies 
on the invasive management and outcomes in a subset of such patients (e.g. ST-elevation myocardial 
infarction (STEMI) or AMI patients with cirrhosis),1,2 and these outcomes have not been 
systematically evaluated across CLD sub-groups. 
What’s new? This is the first study to examine the prevalence, management strategy and clinical 
outcomes of CLD patients hospitalized for AMI from a nationwide perspective. This article shows 
that patients with CLD are significantly less likely to receive invasive management for AMI 
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Introduction: 
Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide.3,4 The most 
common causes of CLD are chronic viral hepatitis (hepatitis B and C), alcohol-related liver disease 
(ALD), and non-alcoholic fatty liver disease (NAFLD). With continued insult, the early stages of 
CLD can progress with worsening fibrosis, leading to cirrhosis and end-stage liver disease. Despite 
the stable prevalence of chronic viral hepatitis and ALD, the overall burden of CLD continues to 
increase, primarily due to a rise in the incidence of NAFLD, which is largely attributed to an increase 
in obesity and diabetes mellitus.3-5 Coronary artery disease (CAD) is common amongst patients with 
CLD, with a 37% prevalence in liver transplant recipients.6-8 CLD patients presenting with acute 
myocardial infarction (AMI), pose a therapeutic dilemma for cardiologists. While their risk of 
cardiovascular mortality is at least as high as patients without CLD, they are at an inherent risk of 
major bleeding complications due to risk factors such as anemia, thrombocytopenia, decreased 
clotting factor synthesis, increased fibrinolysis and renal impairment.9-12 They may be less likely to 
receive guideline-recommended management in the form of percutaneous coronary intervention (PCI) 
and dual-antiplatelet therapy (DAPT) due to these increased risks.13-16 There is limited data on 
management strategies and clinical outcomes for this high-risk group when presenting with AMI from 
a national perspective. While there have been small studies on the utilization of invasive therapies and 
outcomes in a subset of such patients (e.g. ST-elevation myocardial infarction (STEMI) or AMI 
patients with cirrhosis),1,2 these outcomes have not been systematically evaluated across CLD sub-
groups. Using the National Inpatient Sample (NIS), we examined the prevalence of CLD amongst 
patients presenting with AMI over a 12-year period, and evaluated differences in their receipt of 
invasive management and subsequent clinical outcomes, compared to patients without CLD, stratified 
by CLD severity as well as subtype.
Methods
The NIS is the largest publicly available all-payer database of hospitalized patients in the 
United States and is sponsored by the Agency for Healthcare Research and Quality (AHRQ) which 
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primary and secondary discharge diagnoses and procedures from >7 million hospitalizations annually. 
Further information on the design and validation of NIS dataset is provided in Appendix A.
All hospitalized adults (≥18 years) with a principal discharge diagnosis of AMI between 
January 2004 and September 2015 were included. International Classification of Diseases, Ninth 
revision (ICD-9) and Clinical Classification Software (CCS) codes were used to identify patient 
comorbidities, procedures and clinical outcomes (Table S1). Additional comorbidities were identified 
using the existing 29 AHRQ Elixhauser comorbidity measures. Patient characteristics and clinical 
outcomes were stratified according to the presence or absence of CLD. Based on previous findings of 
different CLD etiologies influencing outcomes18 CLD patients were stratified, into 3 groups: chronic 
viral hepatitis, ALD and “other CLD“ (OCLD) diagnoses (Table S1). To further assess differences in 
outcomes based on severity of CLD, groups were stratified into severe and non-severe categories, 
based on the presence of any of the following: portal hypertension, hepatic encephalopathy, 
hepatorenal syndrome and thrombocytopenia and coagulopathy. Cases excluded due to missing data 
for the variables Hospital bedsize and Hospital location/teaching status, and the presence of liver 
transplant represented 0.4% (n=28,752) of the original dataset (Figure S1). Before the exclusion of 
missing data, the dataset has been tested using Little’s MCAR test which showed completely random 
missingness pattern [Chi-square=1.985, DF=2, p=0.371]. These variables were kept in the analysis to 
allow for better understanding of the results and proper adjustment in the multivariable model.
The main outcome was to compare the receipt of invasive management for AMI, in the form 
of coronary angiography (CA), percutaneous coronary intervention (PCI) and coronary artery bypass 
grafting (CABG), and subsequent in-hospital clinical outcomes in patients with and without CLD. In-
hospital complications included major adverse cardiovascular and cerebrovascular events (MACCE), 
all-cause mortality, major bleeding, cardiac complications and acute stroke. MACCE was defined as a 
composite of all-cause mortality, acute stroke/transient ischemic attack (TIA) and cardiac 
complications. Cardiac complications included hemopericardium, cardiac tamponade, coronary 
dissection and any pericardiocentesis procedure. Major bleeding encompassed subarachnoid 
hemorrhage, intracerebral hemorrhage, intracranial hemorrhage, gastrointestinal hemorrhage, 
epistaxis and hemoptysis. All outcomes were based on in-hospital events/procedures irrespectively of 









This article is protected by copyright. All rights reserved
We assessed the normality of data distribution by the Kolmogorov-Smirnov test. Data were 
expressed as median (interquartile range) for continuous non-parametric data and as numbers 
(percentages) for categorical data. Quantitative non-parametric data have been analysed with the 
Mann–Whitney U test and Kruskal-Wallis test, while the Chi-square test was used for the comparison 
of categorical variables between the study groups. Analyses were weighted by the provided discharge 
weights to allow estimation of national averages. All reported data were based on the weighted 
analyses as advised by HCUP. Multivariable logistic regression analysis was performed to determine 
adjusted odds ratios (aOR) of invasive management and adverse outcomes. We have adjusted for all 
baseline covariates that are included in the NIS, which we found both clinically meaningful and 
directly related to in-hospital outcomes. Further information on the statistical analysis and variables 
controlled for is provided on Appendix B. Statistical significance was defined at a level of p<0.05. 
SPSS 25 software (IBM Corp, Armonk, NY) was used for statistical analysis.
Results
After excluding patients due to missing data (Figure S1), a total of 1,458,009 records of AMI 
between 2004 and September 2015 were identified, which corresponded to 7,024,723 hospitalizations. 
There were 6,970,440 patients (99.2%) in the no-CLD group and 54,283 patients (0.8%) in the CLD 
group. Figure 1 displays the trends of CLD rates in AMI hospitalizations. The rate of CLD amongst 
patients hospitalized for AMI has shown a steady increase and more than doubled from 2004 (0.5%) 
to 2015 (1.1%) (p<0.001 for trend). Figure 2 shows the proportion of patients in the different sub-
groups of CLD; other causes accounted for most of these patients (0.4%), followed by chronic 
hepatitis (0.3%) and ALD (0.1%). 
Demographics and comorbid conditions of the 2 groups are displayed in Table 1. Patients in 
the CLD group were more likely to be younger (median age 62 years in CLD group, 68 years in no-
CLD group, p<0.001), male (65.8% in CLD group; 60.3% in no-CLD group, p<0.001), and have a 
higher prevalence of medical comorbidities including anemia, coagulopathy, chronic pulmonary 
disease, diabetes mellitus, drug abuse, fluid and electrolyte abnormalities, and renal failure (p<0.001). 
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Management strategies utilized in the groups are shown in Figure 3A and Table 2. Patients 
with CLD had lower rates of CA (57.5% versus 65.0%, p<0.001) and PCI (31.9% versus 43.3%, 
p<0.001) as compared with no-CLD. The CLD group was less likely to undergo CA and PCI (aOR 
0.62; 95% CI 0.60 to 0.63, and aOR 0.59; 95% CI 0.58 to 0.60), respectively (Figure 4 and Table 3). 
Within the CLD sub-groups, all sub-groups were less likely to receive CA or PCI (p<0.05) (Figure 5 
and Table 3).
When comparing within sub-groups of CLD based on severity, severe form of all sub-groups 
had lower odds of CA and PCI compared to their non-severe counterparts (p<0.05) (Table 3). 
Amongst the severe sub-groups, patients with severe ALD had the lowest odds of CA and PCI, 
followed by patients with the severe form of OCLD; while the chronic viral hepatitis sub-group had 
the most favorable odds of undergoing CA and PCI amongst severe patients (p<0.05) (Table 3). 
A comparison of overall rates of in-hospital outcomes are displayed in Figure 3B and Table 2. 
The rates of MACCE (8.4% in CLD group, 7.0% in no-CLD group, p<0.001), all-cause mortality 
(7.3% in CLD group, 5.7% in no-CLD group, p<0.001), major bleeding (4.7% in CLD group, 2.5% in 
no-CLD group, p<0.001) were higher in patients with CLD, while the rates of cardiac complications 
were similar between the 2 groups (0.1%, p=0.056). 
Figure 6 shows a comparison of inpatient outcomes between the various subgroups of CLD, 
according to severity. Amongst the CLD subtypes, patients with severe forms of OCLD and ALD had 
statistically significantly higher rates of MACCE (17.4% vs. 7.4%, p<0.001 and 15.4% vs. 12.3%, 
p=0.001), mortality (16.1% vs. 6.5%, p<0.001 and 14.2% vs. 11.1%, p<0.001) and major bleeding 
(7.1% vs. 3.9%, p<0.001 and 11.4% vs. 7.2%, p<0.001) compared to their non-severe counterparts, 
even though absolute differences in the ALD sub-group were less obvious. Severe chronic viral 
hepatitis sub-group showed higher rates of major bleeding (3.9% vs. 1.8%, p<0.001) in comparison to 
their non-severe equivalents, while differences in MACCE and mortality were attenuated (7.9% vs. 
6.3%, p=0.026 and 6.0% vs. 5.0%, p=0.128, respectively).
The aORs of adverse events in the CLD group and the different CLD sub-groups are displayed 
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1.15-1.23), all-cause mortality (aOR 1.30, 95% CI 1.25-1.34) and major bleeding (aOR 1.74, 95% CI 
1.67-1.81). However, the odds of stroke was lower in patients with CLD (aOR 0.83, CI 0.77-0.89).
When evaluating CLD sub-groups, most demonstrated higher odds of MACCE, mortality and 
major bleeding (Table 3). Compared to the no-CLD group, the odds of stroke varied amongst the 
CLD sub-groups with lower odds in non-severe OCLD (aOR 0.78, 95% CI 0.69 to 0.87), severe 
OCLD (aOR 0.62, 95% CI 0.40 to 0.97) and severe ALD (aOR 0.59, 95% CI 0.37 to 0.92), but not 
statistically significantly different in other sub-groups (p>0.05) (Figure 5 and Table 3).
When comparing the CLD sub-groups based on severity, severe OCLD patients had higher 
odds of MACCE, mortality and major bleeding compared to their non-severe counterparts; severe 
ALD patients had only higher odds of major bleeding; while  patients with severe form of chronic 
viral hepatitis had lower odds of MACCE and mortality compared to the non-severe subgroup 
(p<0.05) (Table 3). When comparing the severe sub-groups of CLD, patients with OCLD and ALD 
had similarly higher odds of MACCE, mortality and major bleeding (p<0.05) (Table 3).
Following adjustement for differences in baseline characteristics amongst patients who 
underwent PCI, aORs indicated that the odds were significantly higher for MACCE (aOR 1.12, 95% 
CI 1.04 to 1.21), mortality (aOR 1.17, 95% CI 1.08 to 1.28) and major bleeding (aOR 1.65, 95% CI 
1.51 to 1.80; Table S2) in patients with CLD. 
The trends of adverse events are listed in Table S3 and further illustrated in Figure S2. 
Overall, there was a trend for a decline in the odds of MACCE (aOR 1.42 in 2004, 1.05 in 2015), all-
cause mortality (aOR 1.45 in 2004, 1.13 in 2015) and stroke (aOR 1.36 in 2004, 0.82 in 2015), and an 
increase in major bleeding (aOR 1.90 in 2004, 2.16 in 2015), in patients with CLD compared to 
patients without CLD (p<0.001 for trend).
Discussion: 
This is the first study to examine the prevalence, management strategy and clinical outcomes 
of CLD patients hospitalized for AMI from a nationwide perspective. This study shows that the 
prevalence of CLD among patients with AMI has doubled between 2004 and 2015. Patients with CLD 
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CLD, and were overall at a significantly increased risk of all-cause mortality as well as major 
complications including major bleeding. Additionally, we show that the differences in management 
strategies and outcomes of patients with CLD depend on the severity as well as the etiology. In 
comparison to their non-severe counterparts, severe CLD sub-groups had lower odds of CA and PCI, 
while the severe form of OCLD also showed higher MACCE, mortality and major bleeding. In the 
severe disease patients, sub-group with ALD had the lowest odds of CA and PCI, while patients with 
ALD and OCLD had similarly higher risks of MACCE, mortality and major bleeding.
 The trends of CLD rates in patients presenting with AMI have not been systematically 
evaluated. This is the first, large scale evaluation demonstrating that the rates have steadily increased 
and doubled from 0.5% in 2004 to 1.1% in 2015. The rates of CLD in patients presenting with AMI in 
our study was similar to a prior, smaller analysis of the NIS (~10% sample size of the current study), 
that looked at cirrhosis alone and demonstrated a rate of approximately 0.5%.1 Based on 
epidemiological data, the increase in rate of CLD seen in our study over the years is likely related to 
an associated increase in the prevalence of NAFLD in the population.5 
Patients with CLD that have AMI can pose a challenge to treating clinicians when considering 
invasive management strategies. A higher rate of the hematological derangements including anemia 
and coagulopathy can make the use of peri-procedural anticoagulation difficult. Additionally, these 
patients with a higher rate of renal dysfunction have an increased risk of developing contrast-induced 
nephropathy when undergoing invasive management. Expectedly, patients with cirrhosis and end-
stage liver disease who undergo PCI and CABG have a higher risk of complications as well as 
mortality.14-16,19,20 Similar to the findings seen in cirrhosis, patients with CLD have many of these co-
morbidities and thus are also at an increased risk of complications. This can lead to a ‘risk-aversion’ 
tendency among treating physicians leading to lower utilization of invasive procedures in patients 
with CLD. Previous studies that focused on patients with AMI and cirrhosis1,2 found that the 
utilization of invasive management is less in patients with cirrhosis. In this study, that included a 
larger group of patients with CLD, we show for the first time that the utilization of invasive 
management, including CA, PCI, CABG and thrombolytic therapy was lower in patients with CLD 
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that CLD patients undergoing PCI had worse MACCE, mortality and major bleeding, when compared 
to patients without CLD.
This is the first study where differences in management between various sub-groups of CLD 
stratified by severity were analyzed. CA and PCI was used the least among patients with severe forms 
of CLD, with ALD showing the worst utilization as compared to other etiologies of CLD. There are 
many possible reasons for this. Stigmatization of patients that have alcohol dependence/abuse is a 
known phenomenon,21 and can lead to a lower utilization of invasive strategies. ALD patients can also 
present with withdrawal and delirium tremens, making the performance of invasive procedures 
difficult. Also, the rate of progression of liver disease with metabolic and hematological 
abnormalities, in general, is worse in patients with ALD compared to other CLD etiologies 22 and may 
preclude providers from performing invasive procedures more so in this sub-group.  
Prior smaller studies have shown worse outcomes including mortality in patients with cirrhosis 
and AMI,1,2 and this large analysis shows similar findings in the larger group of patients with CLD. 
The higher risk of adverse events in patients with CLD could be related to many of the above-
mentioned co-morbidities such as renal dysfunction and hematological derangements including 
thrombocytopenia, anemia and coagulopathy. Antiplatelet agents and statins, which form the mainstay 
of CAD and AMI therapy, are underutilized in patients with CLD.23 The utilization of invasive 
strategies has been associated with improved outcomes in this patient population,2 which could 
possibly also affect outcomes. Finally there may be an element of selection bias, whereby patients that 
are sicker are less likely to receive PCI and their worse outcomes may not be related to the lack of 
receipt of PCI, but rather to the disease process itself.
Differences in outcomes among the various subgroups of CLD presenting with AMI were also 
evaluated for the first time in this study. In comparison to patients with non-severe disease, sub-
groups with severe form of OCLD have shown higher odds of MACCE, mortality and major 
bleeding, while in the severe disease group, patients with ALD and OCLD did much worse than 
patients with CLD from chronic hepatitis. Interestingly, even though utilization of PCI amongst 
patients with severe disease was lowest in the ALD sub-group, patients with OCLD had similarly 
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patients in the OCLD sub-group most commonly have NAFLD with a small proportion of having 
other relatively rare diseases (such as hemochromatosis, primary biliary cirrhosis, primary sclerosing 
cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency).5 NAFLD patients likely have a similar 
metabolic as well as inflammatory milieu that is seen in patients with CAD. It is possible that the 
‘double-hit’ of cardio-metabolic syndrome and severe hepatic dysfunction could contribute to bad 
outcomes in this group. The relative lack of cardiometabolic risk factors and slighty more appropriate 
utilization of invasive strategies in patients with chronic hepatitis could explain why outcomes in this 
group, while still worse than patients without CLD, were relatively better than other sub-groups of 
severe CLD. 
Interestingly, most of the patients with chronic viral hepatitis showed severe features. Chronic 
viral hepatitis has been previously identified as the strongest predictor of liver cirrhosis, in 
comparison to other etiologies,24 and cirrhosis developing from hepatitis C infection was a leading 
cause of liver transplantation in the United States in 2015.25 Furthermore, it has been shown that large 
proportion of chronic viral hepatitis patients are being underdiagnosed which can contribute to late 
referral after the development of high-risk features.26 Finally, stable prevalence of chronic viral 
hepatitis over the studied period with ageing of the population and advancements in medical treatment 
could influence this subgroup distribution as well.27
The odds of major bleeding were higher in the overall group of patients with CLD, and highest 
amongst those with severe form of ALD and OCLD. This occurred despite a lower utilization of 
invasive management (CA and PCI) in these patients, indicating that these patients had a high 
propensity for bleeding. Amongst patients who did undergo PCI in the CLD group, there was also a 
higher risk of bleeding compared to those without CLD. This underscores the importance of carefully 
weighing risks versus benefits of both medical (especially anticoagulation/antiplatelet agents) and 
invasive strategies in this high-risk group (especially in the ALD and OCLD groups) presenting with 
AMI. Strategies such as radial access, use of less potent antithrombotic agents and third generation 
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In contrast, the odds of ischemic stroke were reduced in the CLD group which was mainly 
driven by the OCLD subgroup. Similar findings have been previously described in another NIS based 
study,32 while a recent meta-analysis on cirrhotic patients revealed no difference in ischemic stroke 
risk.33 Several factors could have a role in the complex interplay of CLD and stroke. It is possible that 
coagulopathy associated with CLD stimulates an antithrombotic milieu by affecting the delicate 
balance between bleeding and thrombosis. Furthermore, the hyperdynamic circulation in CLD could 
have a protective effect on the formation of cerebral ischemic lesions. As previously shown, it is also 
possible that the etiology of CLD has an effect on the association of CLD and stroke.34 Different 
pathophysiology including predominantly impaired inflammatory cascade in chronic viral hepatitis 
and behavioral factors in ALD could lead to a diverse impact on stroke development in comparison to 
the OCLD patient group.
This study has several limitations that are inherent to the nature of analyzing data from an 
administrative dataset which is ICD code dependent and related to a specific hospitalization. There is 
always a possibility of misclassified, incomplete and omitted diagnoses or procedures. The specific 
etiologies of chronic hepatitis and other causes of CLD (eg. NAFLD) are unknown, given the limited 
ICD codes. Patients hospitalized with CLD are more likely to have a type 2 MI from etiologies such 
as sepsis, and associated vasodilatory shock.35,36 It is possible that some of the patients in the CLD 
group of this study were such patients, and hence, it is expected that the role of invasive management, 
as well as overall adverse outcomes would be different in this group. The type of medical 
management (antiplatelet agents, anticoagulation) also plays an important role in outcomes; and are 
not captured for individual patients from this dataset. 
In conclusion, this is the first large study to delineate trends in the rates of CLD in patients 
presenting with AMI, that has steadily increased and doubled over a decade. The odds of invasive 
management are lower, and that of most adverse events are higher in patients with CLD who present 
with AMI. Patients with severe form of ALD had the worst utilization of CA and PCI. Furthermore, 
MACCE, mortality and bleeding were worse in patients with severe form of ALD and OCLD. 
Prospective evaluation of management strategies as well as longer term outcomes in the various sub-
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Figure titles and legends:
Figure 1. Rate of CLD amongst AMI hospitalizations (2004-2015*).
Legend: *2015 – 1st January through 30th September only; AMI – acute myocardial infarction; CLD – chronic liver 
disease.
Figure 2. Frequency of different CLD subtypes in AMI population.
Legend: AMI – acute myocardial infarction; CLD – chronic liver disease. 
Figure 3. Comparison between study groups: A. Invasive management; B. In-hospital outcomes.
Legend: CA – Coronary Angiography; CA – Coronary Artery Bypass Grafting; CLD – chronic liver disease; MACCE – 
major adverse cardiovascular and cerebrovascular events (composite of mortality, cardiac complications and stroke); PCI 
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Figure 4. Adjusted odds ratios (aOR) of outcomes in CLD group*.
Legend: *reference is no CLD group; CLD – chronic liver disease; MACCE – major adverse cardiovascular and 
cerebrovascular events (composite of mortality, cardiac complications and stroke). 
Figure 5. Adjusted odds ratios (aOR) of outcomes in different CLD subgroups*: A. Non-severe 
CLD; B. Severe CLD†.
Legend: *reference is no CLD group; †Presence of portal hypertension, hepatic encephalopathy, hepatorenal syndrome 
and thrombocytopenia and coagulopathy; CA – Coronary Angiography; CLD – chronic liver disease; MACCE – major 
adverse cardiovascular and cerebrovascular events (composite of mortality, cardiac complications and stroke); PCI – 
Percutaneous Coronary Intervention. 
Figure 6. In-hospital outcomes of different CLD subtypes based on disease severity.
Legend: *Presence of portal hypertension, hepatic encephalopathy, hepatorenal syndrome, thrombocytopenia and 
coagulopathy; CLD – chronic liver disease; MACCE – major adverse cardiovascular and cerebrovascular events 
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CLD (0.8%) p-value 
Number of hospitalizations 6,970,440 54,283  
Age (years), median (IQR) 68 (57, 79) 62 (54, 71) <0.001 
Males, % 60.3 65.8 <0.001 
STEMI, % 29.4 20.1 <0.001 
Weekend admission, % 26.0 26.2 0.255 
Primary expected payer, %   <0.001 
Medicare 57.4 51.6  
Medicaid 6.0 14.0  
Private Insurance 27.7 24.0  
Self-pay 5.7 5.7  
No charge 0.6 0.7  
Other 2.7 4.1  
Median Household Income Percentile, %   <0.001 
0-25
th
 28.6 31.2  
26-50
th
 27.3 26.5  
51-75
th
 23.8 22.4  
76-100
th
 20.3 19.8  
Cardiogenic shock, % 5.0 5.4 0.001 
Cardiac arrest, % 1.6 1.9 <0.001 
Ventricular tachycardia, % 2.6 2.7 0.033 
Ventricular fibrillation, % 2.7 2.3 <0.001 
Coronary dissection, % 0.5 0.5 0.874 
Cardiac tamponade, % 0.1 0.0 0.024 
Hemopericardium, % 0.0 0.0 0.329 
Pericardiocentesis, % 0.0 0.0 0.996 
Comorbidities, %    














CLD (0.8%) p-value 
Dyslipidaemia 55.1 44.8 <0.001 
Thrombocytopenia 2.3 12.3 <0.001 
Dementia 1.7 0.8 <0.001 
Smoking history 28.4 31.2 <0.001 
Previous AMI 8.6 7.7 <0.001 
History of IHD 76.9 69.6 <0.001 
Previous PCI 9.7 7.3 <0.001 
Previous CABG 6.1 4.3 <0.001 
Previous CVA 3.1 2.4 <0.001 
Family history of CAD 6.8 4.3 <0.001 
Deficiency anaemias 14.7 23.0 <0.001 
Chronic blood loss anaemia 1.1 2.4 <0.001 
Congestive heart failure 0.9 0.9 0.971 
Chronic pulmonary disease 20.7 28.0 <0.001 
Coagulopathy 4.3 21.0 <0.001 
Depression 6.4 8.9 <0.001 
Diabetes 28.2 33.6 <0.001 
Diabetes with complications 6.1 9.8 <0.001 
Drug abuse 2.0 9.3 <0.001 
Hypertension 66.9 65.6 <0.001 
Hypothyroidism 9.8 10.0 0.126 
Lymphomas 0.5 0.7 <0.001 
Fluid and electrolyte disturbances 19.3 30.1 <0.001 
Rheumatoid arthritis/collagen vascular 
diseases 
2.2 2.6 <0.001 
Metastatic cancer 0.9 1.1 <0.001 
Other neurological disorders 5.8 6.7 <0.001 














CLD (0.8%) p-value 
Paralysis 1.6 1.4 <0.001 
Peripheral vascular disease 10.9 12.2 <0.001 
Psychoses 2.1 4.5 <0.001 
Pulmonary circulation disorder 0.1 0.2 <0.001 
Renal failure (chronic) 16.7 24.0 <0.001 
Solid tumour without metastases 1.4 2.6 <0.001 
Ulcer disease 0.0 0.1 <0.001 
Valvular heart disease 0.2 0.3 0.001 
AIDS 0.1 1.1 <0.001 
Weight loss 2.2 4.2 <0.001 
Hospital bed size, %   <0.001 
Small 10.7 9.7  
Medium 24.9 24.7  
Large 64.5 65.6  
Hospital Region, %   <0.001 
Northeast 19.2 18.0  
Midwest 23.3 18.9  
South 40.0 40.0  
West 17.5 23.1  
Location/ Teaching status, %   <0.001 
Rural 10.2 8.1  
Urban non-teaching 41.1 39.6  
Urban- teaching 48.7 52.4  
Legend: AF: atrial fibrillation; AIDS: acquired immunodeficiency syndrome; AMI: acute myocardial infarction; 
CABG: coronary artery bypass grafting; CAD: coronary artery disease; CLD: chronic liver disease; CVA: 
cerebrovascular accident; IABP: intra-aortic balloon pump; IHD: ischemic heart disease; IQR: interquartile range; 
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MACCE, % 7.0 8.4 <0.001 7.9 6.3 0.026 7.4 17.4 <0.001 12.3 15.4 0.001 
All-cause mortality, 
% 
5.7 7.3 <0.001 6.0 5.0 0.128 6.5 16.1 <0.001 11.1 14.2 <0.001 
Major bleeding, % 2.5 4.7 <0.001 1.8 3.9 <0.001 3.9 7.1 <0.001 7.2 11.4 <0.001 
Cardiac 
complications, % 
0.1 0.1 0.056 0.0 0.0 0.573 0.1 0.3 <0.001 0.1 0.0 0.289 
Postprocedural 
haemorrhage, % 
0.7 0.7 0.295 1.5 1.1 0.165 0.5 1.0 0.013 0.4 0.6 0.205 
Stroke, % 1.5 1.4 0.026 1.9 1.4 0.161 1.2 1.3 0.731 1.7 1.2 0.092 
CA, % 65.0 57.5 <0.001 61.1 62.4 0.368 59.7 40.6 <0.001 49.2 33.4 <0.001 
PCI, % 43.3 31.9 <0.001 35.7 34.9 0.546 34.3 21.1 <0.001 24.4 14.3 <0.001 
CABG, % 8.9 8.6 0.020 6.9 10.0 <0.001 8.6 6.1 0.001 7.0 5.5 0.024 
Thrombolysis, % 1.4 1.0 <0.001 0.8 1.2 0.271 1.0 1.3 0.260 0.9 0.6 0.132 
Use of IABP or 
assist device, % 
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Length of stay 
(days), median 
(IQR) 
3 (2, 6) 4 (2, 7) <0.001 3 (2, 6) 4 (2, 7) 0.001 4 (2, 7) 6 (3, 9) <0.001 5 (3, 8) 5 (3, 10) <0.001 
*Comparison of no-CLD vs. total CLD group; †Comparison of subgroups based on severity within CLD subtype. 
Legend: CA: coronary angiography; CABG: coronary artery bypass grafting; CLD: chronic liver disease; MACCE: major adverse cardiovascular and 
















































OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] 
MACCE 1.19 [1.15, 1.23] 1.26 [1.02, 1.55] 1.04 [0.98, 1.11]†§ 1.10 [1.04, 1.15] 2.08 [1.81, 2.38]†‡ 1.67 [1.56, 1.79] 1.87 [1.63, 2.15]‡ 
Mortality 1.30 [1.25, 1.34] 1.20 [0.95, 1.52] 1.05 [0.98, 1.13]†§ 1.20 [1.14, 1.26] 2.39 [2.07, 2.76]†‡ 1.87 [1.75, 2.01] 2.16 [1.87, 2.50]‡ 
Major 
bleeding 
1.74 [1.67, 1.81] 0.75 [0.50, 1.12] 1.55 [1.43, 1.68]§ 1.52 [1.43, 1.62] 2.11 [1.73, 2.58]†‡ 2.37 [2.18, 2.58] 3.52 [3.02, 4.12]†‡ 
Stroke 0.83 [0.77, 0.89] 1.23 [0.83, 1.83] 0.98 [0.86, 1.12] 0.78 [0.69, 0.87] 0.62 [0.40, 0.97] 1.04 [0.89, 1.22] 0.59 [0.37, 0.92]† 
CA 0.62 [0.60, 0.63] 0.88 [0.78, 1.00] 0.65 [0.63, 0.67]†§ 0.70 [0.68, 0.72] 0.39 [0.35, 0.44]†‡ 0.48 [0.46, 0.50] 0.25 [0.23, 0.28]†‡§ 
PCI 0.59 [0.58, 0.60] 0.83 [0.73, 0.94] 0.60 [0.58, 0.62]†§ 0.67 [0.65, 0.69] 0.44 [0.39, 0.51]†‡ 0.44 [0.42, 0.46] 0.25 [0.21, 0.28]†‡§ 
*Reference group is no chronic liver disease; †Significant difference from non-severe CLD subtype; ‡Significant difference from severe chronic viral hepatitis 
subgroup; §Significant difference from severe ‘other CLD’ subgroup. 
Legend: CA: coronary angiography; CI: confidence interval; CLD: chronic liver disease; MACCE: major adverse cardiovascular and cerebrovascular events 
(composite of mortality, cardiac complications and stroke); PCI: percutaneous coronary intervention. 
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